FDA grants ODD to Keros KER-065 for treatment of Duchenne muscular dystrophy
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Subscribe To Our Newsletter & Stay Updated